Resveratrol in human cancer chemoprevention - Choosing the 'right' dose

There is now robust preclinical evidence to suggest that resveratrol possesses cancer chemopreventive properties. A series of clinical pilot studies has provided insights into its pharmacokinetics, and data on its human antineoplastic pharmacodynamics start to emerge. It is likely that resveratrol w...

Full description

Saved in:
Bibliographic Details
Published in:Molecular nutrition & food research Vol. 56; no. 1; pp. 7 - 13
Main Authors: Scott, Edwina, Steward, William P., Gescher, Andreas J., Brown, Karen
Format: Journal Article
Language:English
Published: Weinheim WILEY-VCH Verlag 01-01-2012
WILEY‐VCH Verlag
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is now robust preclinical evidence to suggest that resveratrol possesses cancer chemopreventive properties. A series of clinical pilot studies has provided insights into its pharmacokinetics, and data on its human antineoplastic pharmacodynamics start to emerge. It is likely that resveratrol will be developed further in the clinic as a putative cancer chemopreventive agent. The question that remains unresolved is: What is the most suitable dose of resveratrol for effective cancer preventive intervention? Mechanistic studies in cells in vitro have almost invariably used concentrations of resveratrol in the 10–5 to 10–4 M range, which is much higher than those which can be achieved in the human biophase after consumption of doses up to 1 g. Many of the preclinical efficacy studies in rodent models of carcinogenesis have employed doses which are dramatically above those which can be ingested with the diet. New experimental paradigms need to be used to obtain information on pharmacological changes elicited by resveratrol when present at very low concentrations or when administered at dietary‐relevant doses.
Bibliography:istex:3DC3E0D46891A44139524997D8D0ED2DDCEDED2D
ArticleID:MNFR201100400
ark:/67375/WNG-JBR3QCGV-T
ISSN:1613-4125
1613-4133
DOI:10.1002/mnfr.201100400